- Home
- DNTH vs WSR Comparison
DNTH vs WSR Comparison
Compare DNTH & WSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- WSR
- Stock Information
- Founded
- DNTH 2015
- WSR 1998
- Country
- DNTH United States
- WSR United States
- Employees
- DNTH N/A
- WSR N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- WSR Real Estate Investment Trusts
- Sector
- DNTH Health Care
- WSR Real Estate
- Exchange
- DNTH Nasdaq
- WSR Nasdaq
- Market Cap
- DNTH 657.0M
- WSR 668.3M
- IPO Year
- DNTH N/A
- WSR 2010
- Fundamental
- Price
- DNTH $19.59
- WSR $12.57
- Analyst Decision
- DNTH Strong Buy
- WSR Strong Buy
- Analyst Count
- DNTH 8
- WSR 2
- Target Price
- DNTH $54.33
- WSR $16.00
- AVG Volume (30 Days)
- DNTH 251.8K
- WSR 249.7K
- Earning Date
- DNTH 05-16-2025
- WSR 04-30-2025
- Dividend Yield
- DNTH N/A
- WSR 4.11%
- EPS Growth
- DNTH N/A
- WSR 26.93
- EPS
- DNTH N/A
- WSR 0.61
- Revenue
- DNTH $6,235,000.00
- WSR $155,128,000.00
- Revenue This Year
- DNTH N/A
- WSR $4.26
- Revenue Next Year
- DNTH N/A
- WSR $4.53
- P/E Ratio
- DNTH N/A
- WSR $20.65
- Revenue Growth
- DNTH 120.63
- WSR 6.69
- 52 Week Low
- DNTH $13.37
- WSR $11.78
- 52 Week High
- DNTH $32.27
- WSR $15.36
- Technical
- Relative Strength Index (RSI)
- DNTH 45.90
- WSR 37.85
- Support Level
- DNTH $20.76
- WSR $12.46
- Resistance Level
- DNTH $22.14
- WSR $12.86
- Average True Range (ATR)
- DNTH 1.50
- WSR 0.29
- MACD
- DNTH -0.13
- WSR -0.01
- Stochastic Oscillator
- DNTH 5.53
- WSR 48.47
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About WSR Whitestone REIT
Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.